This is the second renewal application for the UC Davis postdoctoral T32 program in Oncogenic Signals and Chromosome Biology seeking funding for years 11-15. This training program takes advantage of the integrated strength of the Molecular Oncology Program at the UC Davis NCI-designated Comprehensive Cancer Center and the exceptional expertise and training records of the participating faculty members in oncogenic signals and chromosome biology. The program involves 18 trainers, including two National Academy members and one HHMI Investigator, plus five junior mentors in an effort to develop the next generation of trainers. Every trainer maintains an active, extramurally funded research program. The translational aspects of this program are facilitated by a strong clinical research component at the Cancer Center, with further support from the UC Davis Clinical and Translational Science Center. Over the first two funding periods, the training program appointed an outstanding cohort of 27 highly talented postdoctoral fellows including 8 from underrepresented minorities and 8 fellows who crossed into cancer biology from very different areas of science. Remarkably, 9 fellows obtained competitive, individual fellowships to continue their training in cancer biology. The training program has developed an innovative and effective array of curricular activities that insures individual flexibility and provides formal training in oncogenic signals and chromosome biology, education in the responsible conduct of research, as well as individualized mentoring and career development. Included in the training curriculum are a rich and diverse array of seminars, conferences, discussion groups, workshops, and retreats that provide opportunities to present research progress and broaden the training experience beyond the trainer's laboratory. The training program added significant value to the university, as it serviced a cohort of 138 including 39 training grant eligible postdoctoral fellows in the last funding period, who actively participate in some training grant activities. An effective administrative structure is in place that is further refined in this renewal. A director administers the program with guidance by an active executive committee, each member of which actively maintains a specific portfolio to enhance the program activities. To further develop the training program, we employ the help of a four-member Advisory Board. The two external advisors have experience as directors of comparable cancer-oriented training programs. The two internal members are highly experienced mentors and include the Vice Dean of the School of Medicine, who is an authority in mentoring and co-PI of the UC Davis BEST/Future grant supported by NIH. The training program aims to prepare our trainees for rewarding careers in the biomedical workforce and empower them to make informed decisions of the breadth of possible career tracks.

Public Health Relevance

This is the second renewal application of the UC Davis T32 postdoctoral training grant in Oncogenic Signals and Chromosome Biology, which is closely aligned with the Molecular Oncology Program of the NCI- designated UC Davis Comprehensive Cancer Center. The program developed a thriving and innovative training environment as well as an effective administrative infrastructure that has been very successful in mentoring 17 highly qualified postdoctoral fellows over the last funding period. The next funding period aims to build upon this success and to further refine the program to prepare our postdoctoral trainees for rewarding careers in the biomedical workforce and empower them to make informed decisions about the breadth of the possible career tracks.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA108459-11
Application #
9147218
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2006-09-01
Project End
2021-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
11
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California Davis
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
Harris, Todd R; Kodani, Sean; Rand, Amy A et al. (2018) Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury. Mol Pharmacol 94:834-841
Lucchesi, Christopher A; Zhang, Jin; Ma, Buyong et al. (2018) Disruption of the Rbm38-eIF4E complex with a synthetic peptide Pep8 increases p53 expression. Cancer Res :
Rand, Amy A; Helmer, Patrick O; Inceoglu, Bora et al. (2018) LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide. Methods Mol Biol 1730:123-133
Rand, Amy A; Barnych, Bogdan; Morisseau, Christophe et al. (2017) Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Proc Natl Acad Sci U S A 114:4370-4375
Barnych, Bogdan; Rand, Amy A; Cajka, Tomas et al. (2017) Synthesis of cyclooxygenase metabolites of 8,9-epoxyeicosatrienoic acid (EET): 11- and 15-hydroxy 8,9-EETs. Org Biomol Chem 15:4308-4313
Yang, Hee Jung; Zhang, Jin; Yan, Wensheng et al. (2017) Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner. Proc Natl Acad Sci U S A 114:11500-11505
Scharadin, Tiffany M; He, Wei; Yiannakou, Yianni et al. (2017) Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. PLoS One 12:e0177761
Zhang, Jin; Lucchesi, Christopher; Chen, Xinbin (2016) A new function for p53 tetramerization domain in cell fate control. Cell Cycle 15:2854-2855
McVey, Mitch; Khodaverdian, Varandt Y; Meyer, Damon et al. (2016) Eukaryotic DNA Polymerases in Homologous Recombination. Annu Rev Genet 50:393-421

Showing the most recent 10 out of 47 publications